Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

Faster, Cleaner, Better.

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Interpace Diag Group (IDXG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners GlobeNewswire - Wed Dec 3, 11:12AM CST

PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan...

Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results GlobeNewswire - Wed Nov 12, 3:01PM CST

● Q3 Revenue of $8.8 million ● Q3 Cash Collections of $10.0 million ● Q3 Thyroid test volume up 12% year-over-year to record levels ● Q3 Thyroid revenue...

Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting GlobeNewswire - Mon Sep 15, 8:15AM CDT

Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular...

Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results GlobeNewswire - Thu Aug 7, 3:05PM CDT

● Q2 Revenue of $9.2 million ● Q2 Cash Collections of $10.8 million ● Q2 Thyroid test volume up 16% year-over-year to record levels ● Q2 Thyroid revenue...

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results GlobeNewswire - Thu May 8, 3:05PM CDT

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk GlobeNewswire - Thu Apr 24, 3:00PM CDT

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results GlobeNewswire - Fri Jan 31, 7:30AM CST

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan GlobeNewswire - Mon Jan 27, 5:30AM CST

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk GlobeNewswire - Thu Jan 9, 5:07PM CST

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results GlobeNewswire - Mon Nov 4, 2024